Icon's quarterly earnings hit by biotech and pharma pullback
Cost and research cuts across biotech and pharma are affecting some of the contracting companies that rely on the industry.
The latest victim is Icon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
